Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

78P - Balancing Efficacy and Safety: Systematic Review of Osimertinib Plus Chemotherapy in advanced EGFR-Mutated NSCLC

Date

28 Mar 2025

Session

Poster Display session

Presenters

Omar Daas

Citation

Journal of Thoracic Oncology (2025) 20 (3): S1-S97. 10.1016/S1556-0864(25)00632-X

Authors

O. Daas1, Y. Refai2, A.E. Alshakhshir3, B.E. Alrabadi2

Author affiliations

  • 1 IAU - The University of Jordan, 11942 - Amman/JO
  • 2 JUST - Jordan University of Science and Technology, Irbid/JO
  • 3 Aqaba Medical Sciences University, Aqaba/JO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 78P

Background

Osimertinib is highly CNS active third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that targets EGFR-TKI-sensitizing mutations and the EGFR-T790M resistance mutation. This systematic review investigates the efficacy and safety of combining chemotherapy with osimertnib in patients with EGFR-mutated advanced NSCLC.

Methods

A literature search, including grey literature, was conducted in PubMed, Scopus, Cochrane Library, and Web of Science from inception to November 2024. The incidence of adverse events was also evaluated as an additional outcome.

Results

Eight studies were included with 1838 unique patients. Osimertinib plus chemotherapy demonstrated superior efficacy to Osimertinib alone in NSCLC tumours with CNS, liver, bone, or extrathoracic metastases, achieving a progression-free survival (PFS) of 25.5 months. Similar trends were observed in Chinese (PFS=27.4 months) and Japanese (PFS=14.5 months) populations. Secondary analyses from the FLAURA-2 trial indicated that patients with CNS metastases derived even more significant benefits than the general population (PFS=30.2 months). Common EGFR mutations, including exon 19 deletions and L858R, were assessed. The TAKUMI trial also evaluated the T790M resistance mutation, confirming consistent results. Patients with increased baseline tumor burden showed more significant benefits from the combination therapy (PFS=27.9 months) compared to Osimertinib alone. Similarly, data from recurrent NSCLC cases supported the combination’s efficacy (PFS=25.2 months). Safety analyses revealed a wide range of severe adverse events (grade 3 or higher), with rates between 20% and 83.8%, primarily due to pneumonia and interstitial lung disease.

Conclusions

Conclusion: Combining osimertinib and chemotherapy improves efficacy in patients with advanced EGFR-mutated NSCLC. The increased incidence of adverse effectswarrants careful patient selection. Further research is needed to optimize treatment strategies.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.